Ignite Creation Date:
2024-05-05 @ 10:09 PM
Last Modification Date:
2024-10-26 @ 10:14 AM
Study NCT ID:
NCT01040871
Status:
COMPLETED
Last Update Posted:
2014-01-13
First Post:
2009-12-29
Brief Title:
Study of the Combination of VELCADE Rituximab Cyclophosphamide Doxorubicin and Prednisone or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Open-Label Multicenter Phase 2 Study of the Combination of VELCADE Rituximab Cyclophosphamide Doxorubicin and Prednisone or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized open-label active-control parallel-group multicenter multinational Phase 2 Study of the efficacy and safety of VELCADE Rituximab Cyclophosphamide Doxorubicin and Prednisone VR-CAP or Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone R-CHOP in Patients With Newly Diagnosed Non-Germinal Center B-Cell non-GCB Subtype of Diffuse Large B-Cell Lymphoma DLBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None